 Home > Active Ingredient News > Blood System > Lancet oncol: Loncastuximab tesirine can effectively treat relapsed/refractory DLBCL!

Lancet oncol: Loncastuximab tesirine can effectively treat relapsed/refractory DLBCL!

 Last Update: 2021-05-21
 Source: Internet
 Author: User

Tags

all rubik's cubes

7 11 popcorn

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The prognosis of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that does not respond to salvage treatment or progresses after treatment is often poor.

Lymphoma

This study aims to evaluate the anti-tumor activity and safety of Loncastuximab tesirine in patients with relapsed/refractory DLBCL .

This study aims to evaluate the anti-tumor activity and safety of Loncastuximab tesirine in patients with relapsed/refractory DLBCL

This is an open-label, single-arm phase 2 trial (LOTIS-2) jointly conducted in 28 hospitals in multiple countries, recruiting patients with relapsed/refractory DLBCL who are 18 years of age or older and give them Loncastuximab tesirine (No.

From August 1, 2018 to September 24, 2019, a total of 184 patients were evaluated, of which 145 (79%) were recruited into the trial and received at least one dose of Loncastuximab tesirine, including risk factors for poor prognosis Patients (such as double-strike, triple-strike, or primary refractory DLBCL).

A: Optimal duration of remission; B: progression-free survival; C: overall survival

Among these 145 patients, 70 achieved complete or partial remission (total remission rate 48.

All in all, for previously treated patients with relapsed/refractory DLBCL, Loncastuximab tesirine has potential single-agent anti-tumor activity, can provide long-lasting remission, and has good safety .

For previously treated patients with relapsed/refractory DLBCL, Loncastuximab tesirine has potential single-agent anti-tumor activity, can provide long-lasting remission, and has good safety.

Original source:

Paolo F Caimi, et al.

org/10.
1016/S1470-2045(21)00139-X" target="_blank" rel="noopener">Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

SULODEXIDE 99% Almost White Powder Dideu-01112 Dideu

CAS No.: 57821-29-1

Pharmacy Grade

$61.76/G EXW

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide

CAS No.: 204656-20-2

Pharmacy Grade

$30.00/G FOB

Heparin sodium 9041-08-1 vials safe delivery

CAS No.: 9041-08-1

Pharmacy Grade

$1/G EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.